About

BUS-DDS

The penetration of anti-cancer agents into and throughout solid tumors is widely recognized as a major limitation to their effectiveness.   WellThera’s proprietary platform technology, BUS-DDS, has been developed to enable a step change in the therapeutic index of anti-cancer agents by increasing their dose and distribution within solid tumors without any development costs or delays associated with their reformulation.

This approach can be designed to seamlessly fit into the existing clinical workflows.

Laboratory

https://www.teikyo-dds.com

Advantages of BUS-DDS

  • Targets only cancerous tissue from outside the body (no need for surgery)
  • Treats cancer without surgery
  • Expanded application of anticancer drugs
  • Reduced dosage of anticancer drugs and reduced side effects
  • Application to advanced therapeutic drugs (ADC, nucleic acid drugs)
  • Treatment with nanomedicine by increasing the EPR effect
  • Treatment of cancer in foci with low drug transferability, such as the brain (in cases of tumors, dementia, and other neurological diseases), pancreas and bile duct

“Theranostics Bubble” is a freeze-dried formulation

“Theranostics Bubble” is supplied as a freeze-dried formulation.  At the time of use, simply add 2 mL of water for injection and shake gently.

© WellThera Co., Ltd.